Abstract
Rationale: A 12-wk, open-label study demonstrated the safety and efficacy of teduglutide (TED) treatment in children with SBS‒IF.1 This 24 wk, phase 3 study (NCT02682381; EudraCT 2015-002252-27) assessed the safety and efficacy of 0.025 and 0.05 mg/kg TED in children with SBS‒IF.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
